Navigation Links
Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer
Date:1/19/2009

ders can quickly monitor and effectively manage their patients' care.

The i-STAT(R) System

The i-STAT System accelerates the availability of critical test information that clinicians require to make rapid triage and treatment decisions when diagnosing a patient's condition or monitoring a patient's treatment response. Weighing only 18 ounces, the i-STAT System is an easy-to- use handheld analyzer capable of providing time-sensitive test results at the patient's side in just minutes. To perform a test, the user places two or three drops of whole blood on the test cartridge, which is then inserted into the analyzer. A new test cartridge is used for each patient. Utilizing test- specific cartridges that are fully self-contained, the i-STAT System delivers lab-accurate testing for blood gases, electrolytes, chemistries, coagulation, hematology, glucose and cardiac markers. i-STAT is at the forefront of expanding the possibilities with the industry's most comprehensive panel of bedside tests on a single platform. The i-STAT System is currently used in more than 1,800 hospitals where rapid test results are critical for better patient care. The system is used in emergency departments, intensive care units, operating rooms, as well as catheterization laboratories, outpatient clinics and physician offices.

About Abbott Point of Care

Abbott Point of Care, headquartered in Princeton, NJ, develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis. The company's premier product is the i- STAT, a market-leading handheld blood analyzer capable of performing a panel of commonly ordered blood tests on two or three drops of blood at the patient's side. (http://www.abbottpointofcare.com)

About Abbott

Abbott is a global, broad-based health care company
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
2. Halo Pharmaceutical, Inc. Acquires Whippany Manufacturing Facility from Abbott
3. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
4. Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
5. Abbott to Present at J.P. Morgan Healthcare Conference
6. (Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
7. Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
8. Abbott Declares 340th Consecutive Quarterly Dividend
9. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
10. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
11. EGFR-targeting antibody licensed to Abbott
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... TN (PRWEB) July 31, 2014 Dr. ... was one of the first surgeons in the United States ... iStent, the smallest medical device ever approved by ... first surgeons to recognize the benefits of using a procedure ... with glaucoma. Dr. Shofner and his colleagues now recognize that ...
(Date:7/31/2014)... 31, 2014 Niche Profit Classroom, a method ... is designed to provide a blueprint for anyone who is ... Shane Michaels, prompting an investigative review. , Learn ... speaks volumes about the success of the information in this ... in it have stayed effective even through all of the ...
(Date:7/31/2014)... Los Angeles, CA (PRWEB) July 31, 2014 ... that will benefit both patients and doctors. Doctors will ... are allowed to leave reviews , which guarantees ... different treatment options on the site to receive information ... source. This unprecedented validation system allows Cosmetic Town ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:United Theological Seminary to Open 144th Year 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... ... clinic, recently relocated to a larger office and more convenient location within the ... now located in very close proximity to one of the major medical centers ... 2 massage therapists working collaboratively to help patients get and stay healthy. ...
... , Representatives from Childrens Hospital Los Angeles and childhood cancer patients ... Ceremony. They will dip their hands in fingerpaint and apply ... which is covered in children,s handprints from all over the country, ... The current 80 percent overall cure rate means that in the ...
... A pilot study conducted in a small private high ... benefits of a delayed school start time. Judy Owens, MD, ... modest delay in school start time of only 30 minutes ... health. Her findings are published in the July issue of ...
... ... Talks About America’s Dependence on Fuel, Says President Obama’s New Focus Is Step In ... ... away from relying on petroleum and encouraged the rapid development of alternative energy sources, ...
... ... ... -- “Today’s announcement of a new entity at the United Nations for women and girls ... Harnessing the United Nations’ collective power and authority to advance the rights and needs of ...
... , ... Contest , ... 6, 2010 -- The American Society for Aesthetic Plastic Surgery (ASAPS) is proud ... site for consumers interested in self-improvement. Project Beauty is sponsored by one the leading medical authorities ...
Cached Medicine News:Health News:Boise Acupuncture Clinic Grows into Larger Office 2Health News:New study confirms positive effects of delayed school start times 2Health News:New study confirms positive effects of delayed school start times 3Health News:Los Angeles Alternative Fuel & Auto Expert Available To Speak About Significance of BP Oil Spill 2Health News:New UN Entity Strengthens Global Efforts for Women & Girls 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 2Health News:Aesthetic Society Launches Project Beauty, ,NEW Consumer Website Covering All Things Beauty, 3
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: